Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan;22(1):32-7.
doi: 10.18553/jmcp.2016.22.1.32.

Analysis of Glycemic Control of a Pharmacist-Led Medication Management Program in Patients with Type 2 Diabetes

John J Ko  1 , Jackie Lu  2 , Karen Rascati  3 , Eileen M Stock  4 , Joyce Juan  5 , Kangho Suh  6 , Yoona Kim  7 , Patricia A Tabor  8 , Paul J Godley  9
Affiliations

Analysis of Glycemic Control of a Pharmacist-Led Medication Management Program in Patients with Type 2 Diabetes

John J Ko et al. J Manag Care Spec Pharm. 2016 Jan.

Abstract

Background: An integrated health care system with its own regional health plan located in Texas implemented a pharmacist-led diabetes medication management program (MMP) to treat type 2 diabetic patients (baseline A1c > 7.5%). The MMP formed collaborative practice agreements with the system's physicians to allow ambulatory care pharmacists to modify and adjust diabetic drug regimens when appropriate. Enrolled MMP patients received personalized visits with ambulatory care pharmacists and a copay waiver on diabetes medications.

Objective: To study the outcomes of an outpatient, pharmacist-led MMP, along with a copay waiver on diabetes drugs, in treating adults with type 2 diabetes mellitus over a 2-year period compared with standard care practice.

Methods: This retrospective study employed a quasi-experimental design and used medical claims, pharmacy claims, eligibility data, and electronic medical records. Patients aged 18 to 62 years, who were diagnosed with type 2 diabetes mellitus, and had at least 1 diabetes-related pharmacy claim in the year before the MMP, as well as continuous enrollment in the health plan, were included. Patients enrolled in the pharmacist-led MMP for at least 2 years (n =75) were matched to standard care patients (n =75) on age, gender, baseline A1c, insulin use, and physical comorbidity. The primary outcome was the 2-year change in A1c. Secondary outcomes included inpatient costs, outpatient costs, and pharmacy costs from the baseline period (year before enrollment) compared with the follow-up period (second year of enrollment).

Results: After matching MMP patients (n = 75) to control patients (n = 75), the baseline A1c (9.30 and 9.26), the mean age (53.0 and 53.3, respectively), the Selim Physical Score (3.32 and 3.26, respectively), and the use of insulin (56.0% and 56.0%, respectively) were similar in both groups. MMP patients had a greater mean reduction in A1c compared with standard care patients (-1.24 vs. -0.59, P = 0.009) from baseline to after 2 years. After 2 years, the A1c for MMP patients was significantly lower compared with control patients (8.06 vs.8.67, respectively, P = 0.014). There was also a difference in A1c after 1 year for MMP patients versus control patients (8.18 and 8.69, respectively, P = 0.012).

Conclusions: A pharmacist-led diabetes MMP, combined with a diabetes drug copay waiver, was effective in significantly reducing A1c over a 2-year period for type 2 diabetic patients in this regional health plan.

PubMed Disclaimer

Conflict of interest statement

Scott & White Health Plan supported this research by funding the copay waivers used in this study. Ko was a fellow at Scott & White Health Plan during year 1 of this study and a fellow at Novartis Pharmaceuticals during year 2 of this study. Novartis Pharmaceuticals did not have any input in this study nor did it contribute any funding or support for this research. Ko, Lu, Suh, and Kim were paid fellows at Scott & White Health Plan at the time of this study. The authors declare no other potential conflicts of interest.

Study design was created by Godley, Kim, and Ko, with assistance from Lu, Stock, and Suh. Ko, Juan, Suh, and Tabor collected the data, with data interpretation performed by Stock, Lu, and Rascati. The manuscript was written by Ko, Lu, Stock, and Kim and revised by Ko, Lu, Rascati, and Godley.

References

    1. Dall TM, Zhang Y, Chen YJ, Quick WW, Yang WG, Fogli J.. The economic burden of diabetes. Health Aff (Millwood). 2010;29(2):297-303. - PubMed
    1. Kim S. Burden of hospitalizations primarily due to uncontrolled diabetes: implications of inadequate primary health care in the United States. Diabetes Care. 2007;30(5):1281-82. - PubMed
    1. Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X.. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care. 2010;33(8):1872-894. - PMC - PubMed
    1. Machado M, Bajcar J, Guzzo GC, Einarson TR.. Sensitivity of patient outcomes to pharmacist interventions. Part I: systematic review and metaanalysis in diabetes management. Ann Pharmacother. 2007;41(10):1569-82. - PubMed
    1. Smith M. Pharmacists’ role in improving diabetes medication management. J Diabetes Sci Technol. 2009;3(1):175-79. - PMC - PubMed

Publication types

LinkOut - more resources